Jun 04th 2019

CEPI awards up to US$21 million to Themis for Phase 3 Chikungunya Vaccine Development

May 28th 2019

US patent grants strengthen SNIPR BIOME’s approach to enhance immuno-oncology outcomes by microbiome modulation

More news



Wellington Partners
Life Sciences

A leading European Venture Capital firm investing in early- and growth-stage Life Science companies.



Therapeutics, Medtech, Diagnostics, Digital Health and Biotechnology.

Strong entrepreneurial teams, deep domain knowledge.

Disruptive, innovative tech addressing high unmet medical needs in attractive markets.



Europe, special circumstances US, leader in Germany.

Seed to late-stage, private companies most of the time.

Ticket sizes from €2m up to €20m over the life of the investment.



Managing and investing out of funds WP III and WP IV.

More than €400m of funds raised dedicated to Life Sciences.

Investment Team with strong clinical, scientific and operational backgrounds.